Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L, Lissitchkov T, Dobaczewski G, Klukowska A, Komrska V, Zimmermann R, Auerswald G, Engl W, Abbühl B, Pavlova BG, Ehrlich HJ. Nemes L, et al. Among authors: engl w. Acta Haematol. 2008;119(2):89-97. doi: 10.1159/000118628. Epub 2008 Feb 28. Acta Haematol. 2008. PMID: 18305381 Clinical Trial.
Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH. Auerswald G, et al. Among authors: engl w. Semin Thromb Hemost. 2002 Apr;28(2):203-14. doi: 10.1055/s-2002-27822. Semin Thromb Hemost. 2002. PMID: 11992243 Clinical Trial.
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ. Björkander J, et al. Among authors: engl w. Vox Sang. 2006 May;90(4):286-93. doi: 10.1111/j.1423-0410.2006.00764.x. Vox Sang. 2006. PMID: 16635071 Clinical Trial.
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group. Mannucci PM, et al. Among authors: engl w. Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18. Blood. 2013. PMID: 23777763 Free PMC article. Clinical Trial.
Recruitment update of AHEAD.
Oldenburg J, Zimmermann R, Huth-Kühne A, Kurnik K, Klamroth R, Abraham I, Brondke H, Pirck M, Engl W, Reininger A, Spotts G. Oldenburg J, et al. Among authors: engl w. Hamostaseologie. 2013;33 Suppl 1:S56-60. Hamostaseologie. 2013. PMID: 24344445 Clinical Trial.
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L. Borte M, et al. Among authors: engl w. Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18. Clin Exp Immunol. 2017. PMID: 27613250 Free PMC article. Clinical Trial.
64 results